advertisement
Abstract #8417 Published in IGR 5-1
Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous beagle
Gelatt KN; MacKay EOJournal of Ocular Pharmacology and Therapeutics 2002; 18: 525-534
The changes in intraocular pressure (IOP) and pupil size in glaucomatous dogs were evaluated after instillation of 0.03% bimatoprost (Lumigan, Allergan, Irvine, CA USA) once in the morning, or once in the evening, or twice daily in five day multiple dose studies. Applanation tonometry (IOP) and pupil size (PS) measurements were obtained at 8 a.m., 10 a.m., 12 noon, 2 p.m., and 4 p.m. in eight glaucoma dogs. Methylcellulose (0.5% as placebo) was instilled in the control eye, and 0.03% bimatoprost in the opposite drug eye. Methylcellulose (0.5%) and 0.03% bimatoprost were instilled the second through the fifth days with instillations in the morning (8:30 a.m.) or evening (8 p.m.), or twice daily (8:30 a.m. and 8 p.m.). The mean ± SEM diurnal changes in IOP from baseline values after 0.03% bimatoprost at 8 a.m. once daily for the next four days were 25.0 ± 3.2, 25.6 ± 2.9, 25.5 ± 3.0, and 26.0 ± 3.2 mmHg, respectively, and were significantly different from the control eye. After bimatoprost was instilled at 8 p.m., the mean ± SEM changes in IOP from baseline values in the drug eyes were 27.3 ± 2.4, 26.6 ± 2.2, 27.2 ± 2.5, and 27.3 ± 2.6, respectively. When 0.03% bimatoprost was instilled twice daily, the mean ± SEM changes in IOP from baseline values were 39.1 ± 2.3, 39.9 ± 2.2, 39.9 ± 2.3, and 39.6 ± 2.1 mmHg, respectively, and were significantly different from the control eyes. Miosis of varying duration was frequent during the three studies. Bimatoprost instilled once daily (a.m. or p.m.) as well as twice daily produces significant decreases in IOP and PS in the glaucomatous beagle.
Dr. K.N. Gelatt, Department of Small Animals Clinical Sciences, College of Veterinary Medicine, University of Florida, P.O. Box 100126, Gainesville, FL 32610-0126, USA
Classification:
5 Experimental glaucoma; animal models
11.4 Prostaglandins (Part of: 11 Medical treatment)
